GSK, Alector Partner to Develop Antibodies for Neurodegenerative Diseases
July 02 2021 - 8:22AM
Dow Jones News
By Jaime Llinares Taboada
GlaxoSmithKline PLC said Friday that it has entered into a
collaboration with Alector Inc. for the development and
commercialization of two clinical stage monoclonal antibodies for
neurodegenerative diseases.
The London-listed healthcare company said that Alector will
receive $700 million in upfront payments and might receive an
additional $1.5 billion in clinical development, regulatory and
commercial launch-related milestone payments.
GSK said enrolment is currently underway for a Phase 3 trial for
the AL001 antibodies, while AL101 is in Phase 1a clinical
trial.
Both companies have agreed to co-commercialize and share profits
in the U.S. GSK will retain exclusive commercialization rights
outside the U.S.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
July 02, 2021 08:08 ET (12:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
